Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABSTRAL vs BACTRIM DS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
BACTRIM DS is a combination of sulfamethoxazole and trimethoprim. Sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA), while trimethoprim inhibits dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate. This sequential blockade of folic acid synthesis leads to bactericidal action.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
FDA-approved: Urinary tract infections, acute otitis media, acute exacerbations of chronic bronchitis, traveler's diarrhea, shigellosis, Pneumocystis jirovecii pneumonia (PCP), toxoplasmosis,Off-label: Methicillin-resistant Staphylococcus aureus (MRSA) infections, Stenotrophomonas maltophilia infections, nocardiosis, Wegener's granulomatosis (as second-line therapy), inflammatory bowel disease
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
One double-strength tablet (trimethoprim 160 mg-sulfamethoxazole 800 mg) orally every 12 hours.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Sulfamethoxazole: 8-10 hours; Trimethoprim: 8-12 hours; prolonged in renal impairment (creatinine clearance <30 m L/min: up to 24-48 hours).
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Sulfamethoxazole is metabolized primarily by N-acetylation and glucuronidation; trimethoprim is metabolized by O-demethylation and N-oxidation. Both are eliminated renally via glomerular filtration and tubular secretion.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Renal: 50-70% as sulfamethoxazole (unchanged and acetylated metabolite), 40-60% as trimethoprim (unchanged); biliary: <10% for both; fecal: <4%.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Sulfamethoxazole: 68% bound (albumin); Trimethoprim: 44% bound (albumin, alpha-1-acid glycoprotein).
4-6 L/kg; large Vd indicates extensive tissue distribution
Sulfamethoxazole: 0.21 L/kg; Trimethoprim: 1.3-1.8 L/kg (wide distribution, higher in tissues than plasma).
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Oral: >90% for both components; IV: 100%.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Cr Cl >30 m L/min: No adjustment; Cr Cl 15-30 m L/min: 50% of usual dose every 12 hours; Cr Cl <15 m L/min: Not recommended.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Use with caution, no specific dose recommendation; Child-Pugh Class C: Contraindicated.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Based on trimethoprim component: 8 mg/kg/day of trimethoprim divided every 12 hours. For severe infections, up to 20 mg/kg/day of trimethoprim divided every 6 hours.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Monitor renal function; adjust dose based on Cr Cl. Increased risk of hyperkalemia and folate deficiency; consider folate supplementation.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
BACTRIM DS carries a black box warning for severe hypersensitivity reactions including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and fulminant hepatic necrosis. Also warns about fatal reactions such as agranulocytosis, aplastic anemia, and other blood dyscrasias. Additionally, use in pregnancy at term may cause kernicterus in the newborn.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity reactions: risk of SJS/TEN, especially in patients with HIV, folate deficiency, or genetic susceptibility (e.g., HLA-B*1502, HLA-A*3101). Discontinue at first sign of rash.,Hematologic toxicity: monitor CBCs; caution in patients with folate deficiency, renal impairment, or prolonged therapy.,Hepatic toxicity: can cause cholestatic jaundice, hepatic necrosis; avoid in hepatic impairment.,Renal toxicity: maintain adequate hydration to prevent crystalluria; adjust dose in renal impairment.,Hyperkalemia: risk with high-dose trimethoprim; monitor potassium, especially in patients with renal dysfunction or on potassium-sparing diuretics.,Hypoglycemia: risk in patients with renal impairment or malnutrition; caution with sulfonylureas.,Photosensitivity: avoid excessive sun exposure.,Pregnancy: avoid at term due to risk of kernicterus; use only if benefit outweighs risk.,Lactation: caution due to potential for kernicterus in infants with G6PD deficiency.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Hypersensitivity to sulfamethoxazole, trimethoprim, or any component.,History of drug-induced immune thrombocytopenia with sulfonamides or trimethoprim.,Severe hepatic disease (e.g., acute hepatitis, cirrhosis with jaundice).,Severe renal impairment (Cr Cl <15 m L/min) unless dialysis is available.,Megaloblastic anemia due to folate deficiency.,Pregnancy at term and nursing mothers (due to risk of kernicterus).,Concurrent use with dofetilide (increased risk of arrhythmias).,Infants <2 months of age (sulfonamides can cause kernicterus).
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Avoid high-potassium foods (e.g., bananas, oranges, potatoes) as trimethoprim can increase serum potassium. Avoid alcohol, which may cause disulfiram-like reaction (flushing, nausea, tachycardia). No significant food-drug interactions beyond potassium and alcohol.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
First trimester: Folate antagonist; associated with neural tube defects, cardiovascular malformations, and cleft palate. Second trimester: Growth restriction, preterm birth. Third trimester: Kernicterus risk due to bilirubin displacement from albumin. Avoid during entire pregnancy.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Breastfeeding safety: Both trimethoprim and sulfamethoxazole are excreted into breast milk; M/P ratio for trimethoprim ~1.25, sulfamethoxazole ~0.15. Caution in infants under 2 months or with G6PD deficiency; theoretical risk of kernicterus.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
No standard dose adjustment recommended; avoid use if possible. If necessary, ensure adequate folic acid intake; may need to increase dose due to increased clearance in pregnancy, but specific data lacking.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Bactrim DS (sulfamethoxazole/trimethoprim) is contraindicated in G6PD deficiency due to risk of hemolytic anemia. Monitor for hyperkalemia, especially in elderly or those with renal impairment. Caution with warfarin (potentiates anticoagulation). Avoid in pregnancy (teratogenic) and lactation. Use with caution in folate deficiency; supplement folate if needed.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
Take with a full glass of water and stay well-hydrated to prevent crystalluria.,Avoid prolonged sun exposure; use sunscreen as this drug may cause photosensitivity.,Complete the full course even if you feel better to prevent antibiotic resistance.,Report any skin rash, sore throat, fever, or unusual bleeding immediately.,Do not take if you are pregnant, planning to become pregnant, or breastfeeding.,Inform your doctor if you have kidney disease, G6PD deficiency, or are on blood thinners.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABSTRAL vs BACTRIM DS, answered by our medical review team.
ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. BACTRIM DS is a Sulfonamide Antibiotic Combination that works by BACTRIM DS is a combination of sulfamethoxazole and trimethoprim. Sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA), while trimethoprim inhibits dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate. This sequential blockade of folic acid synthesis leads to bactericidal action.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABSTRAL and BACTRIM DS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. The standard adult dose of BACTRIM DS is: One double-strength tablet (trimethoprim 160 mg-sulfamethoxazole 800 mg) orally every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABSTRAL and BACTRIM DS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. BACTRIM DS is classified as Category C. First trimester: Folate antagonist; associated with neural tube defects, cardiovascular malformations, and cleft palate. Second trimester: Growth restriction, preterm birth. Third . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.